The potency and safety of Semaglutide have not been studied, and thus it has not been established for patients between 65 years and 75 years
Additionally, some patients reach their weight goals within 34 months, while others benefit from staying on the medication longer, often up to a year
Regarding approved uses, tesofensine is specifically used to treat obesity, while semaglutide is indicated for both type 2 diabetes and obesity management
Ernsberger P et al (1987): Clonidine binds to imidazole binding sites as well as alpha 2-adrenoceptors in the ventrolateral medulla
Depending on the nature of the request, in line with ethics approval, the study protocol and participant consent form, further approvals may be required from the Joint Research Office (UCL) or NHS Research Ethics Committee